LORD, ABBETT & CO. LLC - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 368 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2024. The put-call ratio across all filers is 0.98 and the average weighting 0.2%.

Quarter-by-quarter ownership
LORD, ABBETT & CO. LLC ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q2 2024$43,386
+32.6%
633,458
+34.0%
0.14%
+34.3%
Q1 2024$32,710
-40.9%
472,687
-38.8%
0.11%
-45.7%
Q4 2023$55,360
+63.0%
772,967
+18.5%
0.20%
+56.7%
Q3 2023$33,964
-58.5%
652,030
-49.6%
0.13%
-55.0%
Q2 2023$81,858
+114.7%
1,292,768
+83.6%
0.28%
+104.3%
Q1 2023$38,118
-18.8%
703,931
-20.7%
0.14%
-17.9%
Q4 2022$46,959
-100.0%
887,373
-56.0%
0.17%
-51.0%
Q3 2022$93,929,000
-11.1%
2,018,686
+9.1%
0.34%
-8.3%
Q2 2022$105,652,000
-12.9%
1,850,949
-6.6%
0.37%
+15.8%
Q1 2022$121,239,000
+8.7%
1,981,356
-7.0%
0.32%
+27.2%
Q4 2021$111,527,000
+43.3%
2,130,820
+2.0%
0.25%
+36.6%
Q3 2021$77,842,000
-11.1%
2,088,034
-2.7%
0.19%
-11.8%
Q2 2021$87,583,000
+21.6%
2,145,588
+1.1%
0.21%
+15.3%
Q1 2021$72,004,000
+2761.8%
2,122,140
+3174.1%
0.18%
+2187.5%
Q2 2016$2,516,000
-40.2%
64,816
-57.2%
0.01%
-38.5%
Q1 2016$4,206,000
-58.0%
151,264
-18.7%
0.01%
-56.7%
Q4 2015$10,007,000
+83.6%
186,033
+36.7%
0.03%
+87.5%
Q3 2015$5,450,000136,1190.02%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q2 2024
NameSharesValueWeighting ↓
Sarissa Capital Management LP 360,000$11,502,0002.65%
Redmile Group, LLC 610,171$19,495,0001.60%
Pier Capital, LLC 257,256$8,219,0001.18%
WALL STREET ASSOCIATES 358,857$11,465,0001.08%
SENZAR ASSET MANAGEMENT, LLC 161,300$5,154,0000.88%
Rhenman & Partners Asset Management AB 206,000$6,582,0000.79%
EAM Investors, LLC 152,389$4,869,0000.57%
EDMOND DE ROTHSCHILD (SUISSE) S.A. 50,000$1,598,0000.51%
Visium Asset Management, LP 1,051,479$33,595,0000.48%
SPHERA FUNDS MANAGEMENT LTD. 128,000$4,090,0000.40%
View complete list of INTRA CELLULAR THERAPIES INC shareholders